Petros Pharmaceuticals (PTPI) Competitors

$0.0069 +0.00 (+11.29%)

As of 01:13 PM Eastern

PTPI vs. CNSP, PRPH, PRFX, HEPA, and BPTSY

Should you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include CNS Pharmaceuticals (CNSP), ProPhase Labs (PRPH), PainReform (PRFX), Hepion Pharmaceuticals (HEPA), and Biophytis (BPTSY). These companies are all part of the "pharmaceutical products" industry.

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

: Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
CNS Pharmaceuticals N/A N/A -$15.85M -$41.30 N/A
: Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Petros Pharmaceuticals N/A -78.22% -23.50%
CNS Pharmaceuticals N/A -164.56% -130.05%
: 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Petros Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500.
: CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 179.72%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
CNS Pharmaceuticals
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.97 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.
Company Overall Sentiment
Petros Pharmaceuticals Neutral
CNS Pharmaceuticals Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Positive

Summary

Petros Pharmaceuticals and CNS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

: 9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
ProPhase Labs Neutral
Petros Pharmaceuticals Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProPhase Labs
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Petros Pharmaceuticals
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Petros Pharmaceuticals has higher revenue and earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProPhase Labs $5.06M 0.18 -$53.36M -$3.90 N/A
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
: Petros Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Petros Pharmaceuticals' return on equity of -78.22% beat ProPhase Labs' return on equity.
Company Net Margins Return on Equity Return on Assets
ProPhase Labs -825.01% -482.05% -88.90%
Petros Pharmaceuticals N/A -78.22% -23.50%
: ProPhase Labs has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Company	Overall Sentiment
ProPhase Labs	Neutral
Petros Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.18	-$53.36M	-$3.90	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats ProPhase Labs on 8 of the 12 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to PainReform?

Petros Pharmaceuticals (NASDAQ:PTPI) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

: PainReform's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Petros Pharmaceuticals N/A -78.22% -23.50%
PainReform N/A N/A N/A
: In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.
Company Overall Sentiment
Petros Pharmaceuticals Neutral
PainReform Neutral
: Petros Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
: PainReform has lower revenue, but higher earnings than Petros Pharmaceuticals. PainReform is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
PainReform $20K 38.60 -$5.02M -$736.66 N/A
: 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by company insiders. Comparatively, 34.4% of PainReform shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Petros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
PainReform
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
PainReform	N/A	N/A	N/A

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
PainReform	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A
PainReform	$20K	38.60	-$5.02M	-$736.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

PainReform beats Petros Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

: In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Petros Pharmaceuticals Neutral
Hepion Pharmaceuticals Neutral
: Petros Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.
: 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 8.2% of Petros Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Petros Pharmaceuticals' return on equity of -78.22% beat Hepion Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Petros Pharmaceuticals N/A -78.22% -23.50%
Hepion Pharmaceuticals N/A -812.56% -207.31%
: Petros Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

Summary

Petros Pharmaceuticals beats Hepion Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

How does Petros Pharmaceuticals compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

: 0.1% of Biophytis shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 8.2% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Biophytis' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score.
Company Overall Sentiment
Biophytis Neutral
Petros Pharmaceuticals Neutral
: Petros Pharmaceuticals has higher revenue and earnings than Biophytis.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Biophytis N/A N/A -$18.43M N/A N/A
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
: Biophytis' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Biophytis N/A N/A N/A
Petros Pharmaceuticals N/A -78.22% -23.50%
: Biophytis has a beta of 2.46, meaning that its stock price is 146% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.

Company	Overall Sentiment
Biophytis	Neutral
Petros Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats Biophytis on 4 of the 7 factors compared between the two stocks.

Get Petros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTPI vs. The Competition

Export

Metric	Petros Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$193K	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	0.00	0.96	24.91	23.23
Price / Sales	0.04	120.65	504.56	75.49
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	0.00	7.60	9.67	6.69
Net Income	-$8.16M	-$4.80M	$3.55B	$332.64M
7 Day Performance	N/A	-0.05%	1.70%	2.01%
1 Month Performance	N/A	5.50%	5.62%	9.19%
1 Year Performance	N/A	30.96%	34.42%	39.59%

Petros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTPI Petros Pharmaceuticals	N/A	$0.01 +11.3%	N/A	N/A	$193K	$5.11M	N/A	20
CNSP CNS Pharmaceuticals	2.2472 of 5 stars	$2.22 -2.0%	$20.00 +802.9%	N/A	$1.80M	N/A	N/A	5	News Coverage Positive News Gap Up
PRPH ProPhase Labs	N/A	$0.14 +3.8%	N/A	N/A	$813K	$5.06M	N/A	130
PRFX PainReform	0.3184 of 5 stars	$1.94 -5.1%	N/A	N/A	$780K	$17K	N/A	4
HEPA Hepion Pharmaceuticals	N/A	$0.05 -22.7%	N/A	N/A	$619K	N/A	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTPI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, PRPH, PRFX, HEPA, and BPTSY

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to ProPhase Labs?

Summary

How does Petros Pharmaceuticals compare to PainReform?

Summary

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Biophytis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Petros Pharmaceuticals (PTPI) Competitors

PTPI vs. CNSP, PRPH, PRFX, HEPA, and BPTSY

How does Petros Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to ProPhase Labs?

Summary

How does Petros Pharmaceuticals compare to PainReform?

Summary

How does Petros Pharmaceuticals compare to Hepion Pharmaceuticals?

Summary

How does Petros Pharmaceuticals compare to Biophytis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTPI vs. The Competition

Petros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools